Open AccessDrug-eluting stents and acute myocardial infarction: A lethal combination or friends?
Author(s) -
S Otsuki,
Manel Sabaté
Publication year - 2014
Publication title -
world journal of cardiology
Language(s) - English
Resource type - Journals
ISSN - 1949-8462
DOI - 10.4330/wjc.v6.i9.929
Subject(s) - medicine , percutaneous coronary intervention , restenosis , myocardial infarction , paclitaxel , bare metal , stent , drug eluting stent , sirolimus , cardiology , drug , conventional pci , revascularization , pharmacology , chemotherapy
Primary percutaneous coronary intervention is the preferred reperfusion strategy for patients presenting with ST-segment elevation myocardial infarction (STEMI). First generation drug-eluting stents (DES), (sirolimus drug-eluting stents and paclitaxel drug-eluting stents), reduce the risk of restenosis and target vessel revascularization compared to bare metal stents. However, stent thrombosis emerged as a major safety concern with first generation DES. In response to these safety issues, second generation DES were developed with different drugs, improved stent platforms and more biocompatible durable or bioabsorbable polymeric coating. This article presents an overview of safety and efficacy of the first and second generation DES in STEMI.